Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
Healthcare
$1.05 -0.00%
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
52W Low $0.91High $2.88
Volume 1.87M
Average 2.92M
Income Statement
Follow revenue through to earnings.
Revenue
$6.65M
FY 2025 · Annual
-51.2% YoYOperating Income
-$147.70M
FY 2025 · Annual
Net Income
-$136.31M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M |
| Cost of Revenue | 5.85M | 13.76M | 157.19M | 118.53M | 12.9M |
| Gross Profit | 50M | 82.54M | (93.65M) | (104.9M) | (6.26M) |
| Gross Margin | 89.5% | 85.7% | -147.4% | -769.6% | -94.1% |
| Research & Development | 215.52M | 320.45M | 172.6M | 135M | 107.83M |
| Selling, General & Admin | 57.32M | 84.23M | 96.86M | 90.64M | 46.52M |
| Operating Expenses | 266.99M | 390.93M | 96.86M | 105.38M | 141.45M |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| EBITDA | (206.3M) | (267.96M) | (142.65M) | (176.58M) | (127.02M) |
| EBITDA Margin | -369.4% | -278.3% | -224.5% | -1295.4% | -1911.2% |
| Operating Income | (216.99M) | (308.39M) | (190.51M) | (210.28M) | (147.7M) |
| Operating Margin | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Interest Income | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.84M | 26.67M | 29.58M | 24.01M | 11.39M |
| Income Before Tax | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Pre-Tax Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Net Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (Basic) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| EPS (Diluted) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| 94.75M | 96.83M | 98.41M | 113.69M | 118.79M | |
| 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
FATE Earnings Waterfall · TTM
NASDAQ:FATE · Revenue to Net Income
Key Ratios
EPS$-1.09
Gross Margin-377.3%
Net Margin-2101.6%
P/E Ratio-1.0
P/S Ratio88.0
Analysis
$6.3M of revenue converted into -$129.9M of net income for the selected period. Gross margin is -377.3% and net margin is -2101.6%, showing how much revenue survives after costs and taxes. EPS is $-1.09, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| EFFECT | EFFECT filing | Nov 12, 2026 | |
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 9, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| S-3 | S-3 filing | Nov 5, 2026 |
How much revenue does FATE generate?
Fate Therapeutics, Inc. (FATE) reported $6.65M of revenue in fiscal 2025.
Is FATE profitable?
Fate Therapeutics, Inc. (FATE) reported -$136.31M of net income, with a net margin of -2051.1%.
Continue the stock analysis
Jump to another research area for this company.